Risk Strategy Requirement Change For Low Platelet Counts Drugs, Nplate And Promacta - FDA
Links shared publicly online about this topic.
- 0total visits
Risk Strategy Requirement Change For Low Platelet Counts Drugs, Nplate And Promacta - FDA
The FDA approved changes to the Risk Evaluation and Mitigation Strategies (REMS) for both Nplate (romiplostim) and Promacta (eltrombopag). According to an FDA-initiated review of the current infor
View full resource at medicalnewstoday.com
Most Recently Shared on December 8, 2011 at 11:05 pm By:
Risk Strategy Requirement Change For Low Platelet Counts Drugs, Nplate And Promacta - FDA http://t.co/9SgEQssI #blood #hematology
Also Shared By:
Advertisement
MNT Health News
@mnt_healthnews
Risk Strategy Requirement Change For Low Platelet Counts Drugs, Nplate And Promacta - FDA http://t.co/OGIydEDM #healthnews
1 year ago...